Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 3 4Phase 1/2 4Phase 1 4Phase 2/3 1

Status

Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3Other solid neoplasm 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OTHER × dostarlimab × Clear all
NCT05201547 2025-12-04

DOMENICA

ARCAGY/ GINECO GROUP

Phase 3 Active not recruiting
260 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT06762405 2025-02-18

PREDIR-NEOREC

Centre Hospitalier Universitaire Dijon

Phase 3 Recruiting
68 enrolled
GastrointestinalOther solid neoplasm

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT04679064 2021-08-27

NItCHE-MITO33

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 3 Unknown
427 enrolled
Gynecologic

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase 3 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡